Clinical Trial Update: ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing HS-20093 to Topotecan in relapsed small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• HS-20093
• Topotecan (topotecan)

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Small Cell Lung Cancer | Phase 3 | Status: RECRUITING